Design Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Design Therapeutics es Pratik Shah , nombrado en Aug 2023, tiene una permanencia de 2.75 años. compensación anual total es $3.54M, compuesta por 11.1% salario y 88.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.21% de las acciones de la empresa, por valor de $1.43M. La antigüedad media del equipo directivo y de la junta directiva es de 1.2 años y 5.5 años, respectivamente.
Información clave
Pratik Shah
Chief Executive Officer (CEO)
US$3.5m
Compensación total
| Porcentaje del salario del CEO | 11.14% |
| Permanencia del CEO | 2.8yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 1.2yrs |
| Promedio de permanencia en la Junta Directiva | 5.5yrs |
Actualizaciones recientes de la dirección
Recent updates
GeneTAC Biomarker Progress Will Support Long Term Potential In Genetic Neurologic Disease
Catalysts About Design Therapeutics Design Therapeutics focuses on small molecule GeneTAC candidates that aim to increase endogenous frataxin production in Friedreich ataxia. What are the underlying business or industry changes driving this perspective?
GeneTAC Biomarker Strategy In Friedreich Ataxia Will Transform Long Term Prospects
Catalysts About Design Therapeutics Design Therapeutics is a biotechnology company developing small molecule GeneTACs such as DT-216 to modulate gene expression in genetic diseases like Friedreich ataxia. What are the underlying business or industry changes driving this perspective?Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Design Therapeutics: Not A Complete Washout Despite Setback
Summary Design Therapeutics' GeneTAC platform offers a novel approach to treating genetic diseases using small molecules, which are more stable and easier to deliver than gene therapies. The lead indication, Friedreich's ataxia, showed promising results with DT-216 but faced setbacks due to injection site thrombophlebitis, leading to the development of DT-216P2. Financially, DSGN has a market cap of $283mn and a cash balance of $254mn, providing a cash runway into 2029 despite delays. The new formulation delays the program by 2–3 years, but the company remains a watchlist candidate for its innovative approach and potential. Read the full article on Seeking AlphaDesign Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Design Therapeutics GAAP EPS of -$0.27 misses by $0.02
Design Therapeutics press release (NASDAQ:DSGN): Q2 GAAP EPS of -$0.27 misses by $0.02. Cash, cash equivalents and marketable securities were $359.4 million as of June 30, 2022.We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$70m |
| Dec 31 2025 | US$4m | US$395k | -US$70m |
| Sep 30 2025 | n/a | n/a | -US$67m |
| Jun 30 2025 | n/a | n/a | -US$63m |
| Mar 31 2025 | n/a | n/a | -US$56m |
| Dec 31 2024 | US$790k | US$395k | -US$50m |
| Sep 30 2024 | n/a | n/a | -US$48m |
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$59m |
| Dec 31 2023 | US$6m | US$361k | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$72m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$69m |
| Dec 31 2022 | US$5m | US$338k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$57m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | US$585k | US$310k | -US$36m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$19m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$400k | US$250k | -US$8m |
Compensación vs. Mercado: La compensación total ($USD3.54M) de Pratik está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.70M).
Compensación vs. Ingresos: La compensación de Pratik ha aumentado mientras la empresa no es rentable.
CEO
Pratik Shah (55 yo)
Dr. Pratik Shah, Ph D., is an Executive Chairperson at Design Therapeutics, Inc. since December 2017 and serves as its President, Chief Executive Officer and Principal Financial Officer since August 25, 20...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 2.8yrs | US$3.54m | 0.21% $ 1.4m | |
| Chief Operating Officer | 5.3yrs | US$1.89m | 1.3% $ 8.9m | |
| Chief Medical Officer | 1.1yrs | US$2.03m | sin datos | |
| Co-Founder & Scientific Advisor | no data | sin datos | 12.28% $ 84.1m | |
| Chief Accounting Officer | 4.7yrs | sin datos | sin datos | |
| Chief Technology Officer | 1.2yrs | sin datos | sin datos | |
| General Counsel | no data | sin datos | sin datos | |
| Chief Scientific Officer | 1.2yrs | sin datos | sin datos | |
| Chief of Manufacturing & Product Development | 1.2yrs | sin datos | sin datos | |
| Chief Chemist | 1.2yrs | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de DSGN no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 8.4yrs | US$3.54m | 0.21% $ 1.4m | |
| Co-Founder & Scientific Advisor | no data | sin datos | 12.28% $ 84.1m | |
| Independent Director | 5.5yrs | US$120.71k | 0.092% $ 632.3k | |
| Independent Director | less than a year | US$223.78k | sin datos | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | 6.8yrs | US$239.04k | 0.21% $ 1.5m | |
| Lead Independent Director | 6.3yrs | US$136.67k | 0.13% $ 893.2k | |
| Independent Director | 4.9yrs | US$109.71k | 0.0021% $ 14.3k |
Junta con experiencia: La junta directiva de DSGN se considera experimentada (5.5 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/24 09:01 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Design Therapeutics, Inc. está cubierta por 9 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ioannis Souroutzidis | Cantor Fitzgerald & Co. |
| Adam Vogel | Craig-Hallum Capital Group LLC |
| Madhu Kumar | Goldman Sachs |